SS-31 Peptide – Research Grade
SS-31, also known as Elamipretide, is a synthetic tetrapeptide studied in controlled laboratory environments for its relevance to mitochondrial function, cellular energy regulation, and oxidative stress research models. This peptide is supplied strictly for scientific and experimental research purposes and is not intended for clinical, diagnostic, or therapeutic use.
Manufactured using advanced solid-phase peptide synthesis (SPPS), SS-31 is purified to a high degree to ensure molecular integrity, batch-to-batch consistency, and analytical reliability. Each production lot is verified using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm molecular identity, purity, and structural accuracy.
Research Characteristics
- Peptide Name: SS-31 (Elamipretide)
- Amino Acid Length: 4 residues
- Peptide Class: Synthetic mitochondrial-targeted research peptide
- Synthesis Method: Solid-phase peptide synthesis (SPPS)
- Purity: ≥ 99% (HPLC verified)
- Form: Lyophilized powder
- Stability: Stable under recommended laboratory storage conditions
Experimental Applications
SS-31 is commonly utilized in in-vitro and pre-clinical research models investigating mitochondrial membrane interactions, bioenergetic signaling pathways, oxidative stress modulation, and cellular resilience mechanisms. Its application is strictly limited to controlled laboratory studies requiring high-purity and well-characterized peptide materials.
Quality & Documentation
Each batch of SS-31 undergoes comprehensive quality control testing to ensure molecular accuracy, purity, and reproducibility prior to release. Certificates of Analysis (COA) are provided with each order to support research validation, traceability, and experimental documentation requirements.
Important Notice: This product is intended for laboratory research use only and is not for human or animal consumption. It is not intended for diagnostic, therapeutic, or clinical applications of any kind.





Reviews
There are no reviews yet.